LEXINGTON, Mass., May 18, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) today announced that new data from a Phase 2 trial testing the Prophage G-200 vaccine (HSPPC-96; vitespen) in recurrent ...
LEXINGTON, Mass., June 6, 2011 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN), a leading developer of therapeutic vaccines for cancer and infectious diseases, today announced results from a Phase 2 ...
A phage is a virus that invades a bacterial cell. While harmless to human cells, phages are potentially deadly to bacteria since many phages enter a cell in order to hijack its machinery in order to ...
In a recent study published in the journal PLoS Pathogens, researchers analyze prophages of the LF82 strain of adherent-invasive Escherichia coli (AIEC) to better understand their behavior in vitro ...
Lexington, MA – Jan. 14, 2014 – Agenus Inc. (NASDAQ: AGEN), a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, today announced initiation ...
New Phase 2 Data From Brain Cancer Study With Agenus' Prophage Vaccine (HSPPC-96) Presented at Plenary Session of AANS LEXINGTON, Mass., April 17, 2012 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) ...
Intron Biotechnology Inc. has announced the identification of lysogenic bacteriophages prophage and jamphage in the pancreatic cancer-related microbiome. This identification was achieved as part of ...
The dose-response relationship for the induction of λ-prophage is a composite of the induction process and the capacity for phage development. Consequently, the character of the relation is hard to ...
Researchers have uncovered a two-component system of Butters prophage genes that encode proteins that 'collaborate' to block entry and subsequent infection of some phages, but not others. Their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results